


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



ATTY. DOCKET NO. 077319/0125

In re Patent Application of

David W. LEUNG et al.

Serial No. 08/842,827 ATTN: Application Division

Filed: April 17, 1997

For: HUMAN PHOSPHATIDIC ACID PHOSPHATASE

TRANSMITTAL LETTER

Box Missing Part Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

Responsive to the Notice to File Missing Parts of Application under 37 C.F.R. § 1.53(d) mailed June 9, 1997, attached hereto are the following to complete the formal filing requirements in the above-identified application:

- X Check in the amount of \$530.00 in payment of the \$385.00 official Government filing fee, the \$65.00 surcharge, \$40.00 for independent claim fees over 3 and the \$40.00 Assignment recordation fee.
- X Declaration and Power of Attorney signed by each Inventor.
- X Preliminary Amendment.
- X Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825.
- X Sequence Listing (Paper Copy and Computer Readable Form (CRF) copy).
- X Small Entity Declaration signed by or on behalf of each individual, concern or organization having rights in the subject invention.

Serial No. 08/842,827

- X Assignment to CELL THERAPEUTICS, INC. with Recordation Form Cover Sheet (recordation fee of \$40.00 included in attached check).
- X A copy of the Notice to File Missing Parts of Application (Form PTO-1533) mailed June 9, 1997.
- X A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 9, 1997.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 19-0741.

Receipt is now awaited by Applicants of the official Filing Receipt confirming the above-noted filing date and Serial Number.

Respectfully submitted,

August 5, 1997

Stephen A. Bent Reg. No. 29,768

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, DC 20007-5109
(202) 672-5300



EPARTMENT OF COMMERCE Patent and T

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

TANDE MILL			
APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE

08/842,827

04/17/97

LEUNG

D

1801

077319/0125

06/09/97

0262/0609

FOLEY AND LARDNER SUITE 500 3000 K STREET NW PO BOX 25696 WASHINGTON DC 20007-8696 NOT ASSIGNED

DATE MAILED:

NOTICE TO FILE MISSING PARTS OF APPLICATION

Filing Date Granted	
An Application Number and Filing Date have been assigned to this application. However, the items indicated below are required items and fees identified below must be timely submitted ALONG WITH THE PAYMENT OF A SURCHARGE for 3-6 only of \$	r items 1 and is set forth in ems and pay
If all required items on this form are filed within the period set above, the total amount owed by applicant as a Garge entity Small entity (verified statement filed), is \$	7.
1. The statutory basic filing fee is: missing. insufficient.	*
statement claiming such status (37 CFR 1.27). Additional claim fees of \$	
□ 3. The oath or declaration: □ is missing. □ does not cover the newly submitted items. □ does not identify the application to which it applies. □ does not include the city and state or foreign country of applicant's residence. An oath or declaration in compliance with 37 CFR 1. 63, including residence information and identifying the application Number and Filing Date is required.	lication by
 ✓ 4. The signature(s) to the oath or declaration is/are: ✓ missing. □ by a person other than inventor or person qualified under 37 CFR 1.42, 1.43, or 1.47. A property signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required. 	
5. The signature of the following joint inventor(s) is missing from the oath or declaration:	
An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this ap	plication by
☐ 6. A \$processing fee is required since your check was returned without payment (37 CFR 1.21)	.8)S
☐ 7. Your-filting receipt was mailed in error because your check was returned without payment.	{ & ?
See attached "Notice to Comply with Sequence Rules See Attached "Notice Rules See At	
9. OTHER:	
Direct the response about this notice to "Attention: Box Missing Parts."	1
A copy of this notice MUST be returned with the response.	X 1
Customer Service, Center L	\supset
Initial Patent Examination Division (703) 308-1202	

Application No.: _

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CO. NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.				
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
3 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
7. Other:				
Applicant Must Provide:				
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.				
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these requirements, please contact:				

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE